HEALTH: Summary of Nov 7, 2026

By · Published on

Illustration of virus particles under magnification
AI-generated illustration; does not depict the actual event.

Measles cases in the United States reached a 35-year high, Canada approved Moderna’s mRNA flu vaccines, a Korean study tied sugary processed foods to breast cancer risk, Guinea-Bissau scrapped a disputed vaccine trial on babies, and a study found surgery helped patients for whom weight-loss drugs failed.

US measles cases reach their highest level since 1991 as New York records a child’s death

The United States has recorded 5,182 confirmed measles cases so far in 2026, the highest annual total since 1991, according to figures from the Centers for Disease Control and Prevention released on Friday. That compares with 2,289 cases in the whole of 2025. State health officials have reported at least eight measles-related deaths this year, including among very young children, as the disease spreads amid falling vaccination rates and distrust of health authorities.

New York’s health department said a child in Lewis County, in the north of the state, had died, the first measles-associated death in New York in more than 30 years. The state has recorded 178 cases this year, 170 of them outside New York City, and Governor Kathy Hochul declared the outbreak an emergency in October. The CDC sent experts at the state’s request. Neighbouring Pennsylvania has 1,433 cases, 269 hospitalisations and six deaths.

Measles was declared eliminated from the United States in 2000 after decades of vaccination, but it keeps being reintroduced, often by unvaccinated travellers. It is one of the most contagious diseases: an exposed person without immunity has a 95% chance of infection. Two doses of the measles, mumps and rubella vaccine are 97 per cent effective, and health officials in New York urged residents to make sure they are up to date.


Canada becomes the first country to approve Moderna’s mRNA flu vaccine and a flu-Covid combination

Health Canada has authorised Moderna’s mRNA vaccine against influenza and a combined vaccine that protects against both influenza and Covid-19. Canada is the first country to approve both the standalone flu shot and the dual product, extending the company’s authorised range there beyond its Covid-19 vaccines into seasonal respiratory protection. The decision follows the recent approval in the United States of Moderna’s mRNA flu vaccine, sold as Mflusiva.

The approvals test the company’s plan to build a range of vaccines that depends less on Covid-19 sales, with five approved products and two further launches planned for 2026. Moderna faces competition from Pfizer and Novavax in seasonal vaccines. Analysts have noted that expanding respiratory vaccines could draw manufacturing capacity and attention away from its cancer and rare disease programmes, which the company also counts on for long-term growth.

Moderna, founded in 2010 and based in Cambridge, Massachusetts, develops medicines and vaccines that use messenger RNA to carry instructions for making proteins that prompt an immune response. Its first mRNA vaccine, developed in 2015, was against influenza. Its products include the Spikevax Covid-19 vaccine and the Mresvia vaccine against respiratory syncytial virus, and the United States approved Mflusiva for people aged 50 and over in August 2026.


Korean study links frequent sugary processed foods to a higher breast cancer risk

Eating sugary processed foods more than twice weekly was tied to a 28% rise in breast cancer risk, compared with eating them no more than monthly, according to a Korean study in the European Journal of Nutrition. Researchers from Seoul National University College of Medicine and Mokwon University followed 71,264 women aged 40 to 69 for an average of 9.2 years, during which 713 were diagnosed with breast cancer.

Eating ice cream more often than weekly was associated with a 26% increase in risk compared with never eating it, and frequent sweetened cereal was linked to a 34% higher risk. Among women under 50, the risk was 52% higher, while no significant rise appeared in women aged 50 and over. Sugar from fruit showed no clear link. The researchers said the observational study could not prove that the foods cause cancer.

The authors suggested that frequent sugary foods may raise insulin resistance and levels of a growth hormone involved in cell proliferation. Breast cancer is the most common cancer among Korean women, professor Kang Dae-hee said, urging fewer sweetened processed foods. Established risk factors for breast cancer include obesity, lack of exercise, alcohol, early first menstruation, having children late or not at all, older age and family history of the disease.


Guinea-Bissau cancels a US-funded hepatitis B vaccine trial on newborns

Guinea-Bissau has cancelled a proposed trial of the hepatitis B vaccine on newborn babies after international criticism that it was unethical. The study, funded with $1.6m from the US Centers for Disease Control and Prevention, planned to involve 14,000 babies, with one group vaccinated at birth and the other six weeks later. A researcher involved said the trial failed to obtain government approval, calling its end a significant setback for African science.

The World Health Organization called the trial unethical, and experts warned that delaying the vaccine could expose babies to infection in a country where about one in five people has hepatitis B. Magda Robalo, a former health minister, said the researchers had taken advantage of the country’s limited research capacity. The judicial police raided the research group’s premises in mid-October and seized vaccine batches while authorities examined whether safety standards had been met.

The trial was planned by the Bandim Health Project, a research station in Bissau linked to the University of Southern Denmark, which Peter Aaby set up in 1978 and whose claims about the wider effects of vaccines have been questioned by other scientists. Because Guinea-Bissau lacks enough doses, it gives the vaccine up to six weeks after birth, but it plans to begin vaccinating all babies at birth from 2028.


Bariatric surgery brings large weight loss for patients failed by GLP-1 drugs, study finds

Bariatric surgery produced substantial weight loss over two years in patients who could not tolerate semaglutide or tirzepatide or lost too little weight on them, according to a Cleveland Clinic study in the Annals of Surgery. Before surgery, those intolerant of the drugs had gained 1.4% of their weight over two years, and those with an inadequate response had lost 1.5%. After surgery, losses of up to 35.8% were recorded.

The study covered adults with a body mass index of at least 35 who had gastric bypass or sleeve gastrectomy between 2018 and 2024, including 61 who stopped the drugs because of side effects and 207 with a poor response, compared with 4,661 who had never used them. Among poor responders, gastric bypass brought greater weight loss than sleeve surgery, 32.7% against 17.8% after adjustment, said lead author Ali Aminian.

Aminian said the drugs had transformed obesity care but did not work for everyone, and that surgery could be the next step for those patients. Bariatric surgery covers several procedures used to treat obesity, mainly by changing gut hormones that control hunger and fullness and by reducing the size of the stomach. Gastric bypass and sleeve gastrectomy are the two main types, and bypass may offer the largest and most lasting weight loss.

In this topic